Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Public ClinicalTrials.gov record NCT02239146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Study identification
- NCT ID
- NCT02239146
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 43 participants
Conditions and interventions
Interventions
- catridecacog Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 35 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2005
- Primary completion
- Dec 31, 2007
- Completion
- Dec 31, 2007
- Last update posted
- Jan 10, 2017
2005 – 2008
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Tucson | Arizona | 85714 | — |
| Novo Nordisk Investigational Site | San Francisco | California | 94143 | — |
| Novo Nordisk Investigational Site | Denver | Colorado | 80262 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46290 | — |
| Novo Nordisk Investigational Site | Camden | New Jersey | 08103 | — |
| Novo Nordisk Investigational Site | New York | New York | 10032 | — |
| Novo Nordisk Investigational Site | The Bronx | New York | 10461 | — |
| Novo Nordisk Investigational Site | The Bronx | New York | 10467 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44195 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97207 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97239-3098 | — |
| Novo Nordisk Investigational Site | Allentown | Pennsylvania | 18103 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19107-5092 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02239146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2017 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02239146 live on ClinicalTrials.gov.